AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Medicine Advances Article
PDF (281.9 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter to the Editor | Open Access

Tenosynovial Giant Cell Tumor Treatment Revolution: Vimseltinib's Edge Over Pexidartinib

Muhammad Affan Abid ( ), Syed Azfar Hussain, Muhammad Ali Kamal
Department of Bachelors of Medicine and Surgery (MBBS), Dow University of Health Sciences, Karachi, Pakistan
Show Author Information

Graphical Abstract

This paper compares vimseltinib and pexidartinib in treating TGCT, highlighting key differences in their efficacy and safety, with vimseltinib showing better tumor reduction. Vimseltinib is more selective for CSF1R, leading to fewer side effects and no liver toxicity, whereas pexidartinib carries a higher risk of hepatotoxicity. Overall, vimseltinib offers better effectiveness and safety.

References

【1】
【1】
 
 
Crossref Google Scholar
Medicine Advances
Volume 3 Issue 4,
December 2025
Pages 372-373
DOI: 10.1002/med4.70015

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Abid MA, Hussain SA, Kamal MA. Tenosynovial Giant Cell Tumor Treatment Revolution: Vimseltinib's Edge Over Pexidartinib. Medicine Advances, 2025, 3(4): 372-373. https://doi.org/10.1002/med4.70015

1378

Views

39

Downloads

0

Crossref
Received: 18 March 2025
Revised: 02 April 2025
Accepted: 08 April 2025
Published: 13 January 2026
© 2025 The Author(s). Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.